Company Overview
Gain Therapeutics, Inc. operates as a biotechnology firm dedicated to developing novel small molecule therapeutics intended to treat diseases across various therapeutic areas within Switzerland, Spain, the United States, and Australia. The company utilizes its drug discovery platform, Magellan, to identify novel allosteric binding sites in diseases, a process that facilitates the creation of targeted treatments. This entity functions within the Healthcare sector and specifically the Biotechnology industry, positioning it as an entity focused on research and development rather than mature commercial operations. With a market capitalization of $70.39M and an employee base of 23, the company represents a small-cap enterprise typical of early-stage biotechnology firms. The combination of a sub-$100 million market cap and N/A annual revenue indicates that the company is currently in a pre-commercialization or early-stage development phase, where value is derived from intellectual property and pipeline potential rather than established sales streams.
Financial Health
The company reports N/A for Revenue (TTM), while its Net Income (TTM) stands at $-19,391,744 and EBITDA is recorded at $-17,553,668. The significant disparity between the reported N/A revenue and the substantial negative net income reveals a cost structure dominated by high operational expenses, likely driven by research, development, and administrative costs inherent to biotechnology companies without current sales. Free cash flow is reported at $-9,535,148, which indicates that the company is consuming cash reserves to fund its operations and development activities, thereby limiting immediate financial flexibility without external capital raises. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are listed at 0.0%, a figure that reflects the absence of revenue generation and the inability to calculate margins in a traditional sense for a company with no sales. The company holds $8.81M in cash against $605,278 in debt, resulting in a Debt to Equity ratio of 10.24, which suggests a leveraged balance sheet relative to equity but one supported by significant cash liquidity. The Current Ratio is 2.52, indicating that the company possesses 2.52 times more current assets than current liabilities, suggesting adequate short-term liquidity to meet its obligations despite the lack of operational cash flow. Return on Equity is -261.7% and Return on Assets is -86.8%, metrics that reveal management is currently generating significant negative returns on the capital invested by shareholders and the company's asset base due to heavy losses.
Valuation Assessment
The trailing P/E ratio is N/A due to the absence of net income, whereas the Forward P/E is listed at -2.47, a metric that implies expected earnings remain negative in the near term as the company has not yet achieved profitability. The Price to Book ratio is 11.16, indicating that the market values the company's equity at a significant premium of 11.16 times its book value, a common valuation characteristic for biotechnology firms with high intellectual property potential but limited current assets. The Price to Sales ratio is N/A because there is no revenue to measure, and the EV/EBITDA stands at -3.42, suggesting that traditional valuation multiples are not applicable given the lack of positive earnings or sales. The stock has a 52-Week High of $4.34 and a 52-Week Low of $1.41, providing a trading range within which the current price fluctuates based on market sentiment regarding the company's pipeline. The Beta value is -0.02, which is an anomalous statistic for a publicly traded stock that typically implies negligible correlation with or inverse movement relative to the broader market, though such a figure often appears in datasets with specific calculation limitations for small-cap or low-volume stocks.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, which prevents a direct comparison of whether earnings are growing faster or slower than revenue as the company currently generates no sales to measure growth rates. Consequently, the company does not pay dividends, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning the company reinvests all available resources, including its cash reserves, into its drug discovery platform and operational continuity rather than distributing income to shareholders. The overall growth and income profile is characterized by a lack of historical financial growth metrics and an absence of income distribution, focusing entirely on capital preservation and funding future therapeutic development. The combination of N/A growth rates and a 0.0% payout ratio underscores the company's stage of development where survival and pipeline advancement take precedence over shareholder yield.